Puma Biotechnology | PBYI - أصول متداولة





أصول متداولة تغيير تاريخ
Agios Pharmaceuticals USD 717.67M 117.18M 2026-06
Alnylam Pharmaceuticals USD 4.62B 400.86M 2026-06
Amgen USD 34.96B 3.49B 2026-06
Biogen USD 7.31B 1.88B 2026-06
BioMarin Pharmaceutical USD 3.97B 633.45M 2026-06
Daiichi Sankyo JPY 2.23T 91.92B 2026-06
Exelixis USD 1.25B 42.18M 2026-06
Gilead Sciences USD 12.53B 6.11B 2026-06
Glaxosmithkline GBP 17.76B 5.83B 2026-03
Incyte USD 6.03B 542.31M 2026-06
MacroGenics USD 321.69M 139.16M 2026-06
Moderna USD 5.82B 45M 2026-06
Novartis USD 27.35B 744M 2026-06
Pfizer USD 41.36B 1.46B 2026-06
PTC Therapeutics USD 2.62B 363.36M 2026-06
Puma Biotechnology USD 143.58M 7M 2025-09
Regeneron Pharmaceuticals USD 18.45B 236.8M 2026-06
Roche Holding CHF 35.44B 3.29B 2026-06
Sangamo BioSciences USD 49.89M 12.3M 2025-06
Sarepta Therapeutics USD 2.22B 86.05M 2026-06
Takeda JPY 3.15T 59.77B 2026-06
TG Therapeutics USD 1.15B 58.72M 2026-06
Ultragenyx Pharmaceutical USD 606M 51M 2026-06
Vanda Pharmaceuticals USD 347.26M 20.23M 2025-12
Vertex Pharmaceuticals USD 12.54B 813.4M 2026-06